COPD and atrial fibrillation (AF) frequently happen at the same time, and this can lead to worse clinical outcomes than either condition alone. Because inflammation plays a central role in both diseases, researchers have begun to study the value of the systemic immune-inflammation index (SII) as a prognostic tool in patients with both illnesses.
A new study, “Nonlinear Association Between Systemic Immune-Inflammation Index and In-Hospital Mortality in Critically Ill Patients With Chronic Obstructive Pulmonary Disease and Atrial Fibrillation: A Cross-Sectional Study,” was published in the Journal of Thoracic Disease.
According to a news release, the study was intended to investigate the association between the SII and in-hospital mortality in intensive care unit patients with both COPD and AF.
The researchers identified ICU patients from the Medical Information Mart for Intensive Care — a large, single-center database of information about patients admitted to the emergency department or ICU at Beth Israel Deaconess Medical Center in Boston. The study endpoint was mortality, defined as death from any cause and occurring during the hospitalization process.
The researchers found there was an association between the SII and in-hospital mortality. They wrote that the findings position SII as a potentially valuable biomarker for risk stratification in patients with COPD and AF. The identified threshold could serve as a clinical decision point for intensifying monitoring or considering immunomodulatory therapies.
The authors said that future research should validate these findings and explore whether SII-guided management can improve outcomes in this high-risk population.
The researchers found there was an association between the SII and in-hospital mortality. They wrote that the findings position SII as a potentially valuable biomarker for risk stratification in patients with COPD and AF. The identified threshold could serve as a clinical decision point for intensifying monitoring or considering immunomodulatory therapies.
The authors said that future research should validate these findings and explore whether SII-guided management can improve outcomes in this high-risk population.
